Search results for "CIPROFLOXACIN"

showing 10 items of 56 documents

Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract

2013

The objective was to characterize the in vivo absorption and bioavailability (BA) of a low solubility, high permeability fluoroquinolone (CNV97101) that precipitates in the gastrointestinal (GI) tract by mathematical modeling approach. In situ rat intestinal perfusion studies were performed to characterize the absorption mechanism. The oral fraction absorbed in vivo was lower than the predicted based on the in situ intestinal permeability. Two additional routes of administration, intraduodenal (ID) and intraperitoneal (IP) were investigated to explore if precipitation in stomach and subsequent partial re-dissolution were the causes of the lower in vivo BA. Ex vivo precipitation studies with…

Health Toxicology and MutagenesisAdministration OralBiological AvailabilityPharmacologyToxicologyBiochemistryPermeabilityIntestinal absorptionPharmacokineticsCiprofloxacinIn vivomedicineAnimalsChemical PrecipitationChromatography High Pressure LiquidPharmacologyGastrointestinal tractIntestinal permeabilityChemistryStomachGeneral MedicineHydrogen-Ion ConcentrationModels Theoreticalmedicine.diseaseRatsBioavailabilityGastrointestinal Tractmedicine.anatomical_structureIntestinal AbsorptionNonlinear DynamicsSolubilityEx vivoFluoroquinolonesXenobiotica
researchProduct

In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.

2007

The objective was to devise and apply a novel modelling approach to combine segmental in situ rat perfusion data and in vitro cell culture data, in order to elucidate the contribution of efflux in drug absorption kinetics. The fluoroquinolone CNV97100 was used as a model P-gp substrate. In situ intestinal perfusion was performed in rat duodenum, jejunum, ileum and colon to measure the influence of P-gp expression on efflux. Inhibition studies of CNV97100 were performed in the presence of verapamil, quinidine, cyclosporin A and p-aminohippuric acid. Absorption/efflux parameters were modelled simultaneously, using data from both in situ studies as well as in vitro studies. The maximal efflux …

In situAbsorption (pharmacology)MaleColonVasodilator AgentsPharmaceutical ScienceIleumMuscarinic AntagonistsModels BiologicalIntestinal absorptionPermeabilityJejunumCiprofloxacinCyclosporin aIntestine SmallmedicineAnimalsPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Intestinal MucosaRats WistarP-glycoproteinPharmacologybiologyDose-Response Relationship DrugMolecular StructureChemistryGeneral MedicineQuinidineRatsKineticsmedicine.anatomical_structureBiochemistryIntestinal AbsorptionVerapamilbiology.proteinBiophysicsCyclosporinep-Aminohippuric AcidEffluxAlgorithmsImmunosuppressive AgentsFluoroquinolonesBiopharmaceuticsdrug disposition
researchProduct

Enterobacter and Klebsiella species isolated from fresh vegetables marketed in Valencia (Spain) and their clinically relevant resistances to chemothe…

2013

Occurrence of antibiotic-resistant pathogenic or commensal enterobacteria in marketed agricultural foodstuffs may contribute to their incorporation into the food chain and constitutes an additional food safety concern. In this work, we have determined the clinically relevant resistances to 11 common chemotherapeutic agents in Enterobacter and Klebsiella isolates from fresh vegetables from various sources (supermarkets and greengrocers' shops in Valencia, Spain). A total of 96 isolates were obtained from 160 vegetables analyzed (50% positive samples): 68 Enterobacter isolates (59 E. cloacae, two E. aerogenes, two E. cancerogenus, one E. gergoviae, and four E. sakazakii, currently Cronobacter…

KlebsiellaFood SafetyEnterobacterCeftazidimeFood ContaminationMicrobial Sensitivity TestsApplied Microbiology and BiotechnologyMicrobiologyMicrobiologyClavulanic acidKlebsiellaDrug Resistance BacterialVegetablesmedicinePrevalenceHumansCronobacterbiologyEnterobacteriaceae InfectionsEnterobacterbiology.organism_classificationAnti-Bacterial AgentsCiprofloxacinSpainAnimal Science and ZoologyGentamicinFood Sciencemedicine.drugFood contaminantFoodborne pathogens and disease
researchProduct

Kinetic modelling of the intestinal transport of sarafloxacin. Studiesin situin rat andin vitroin Caco-2 cells

2005

The absorption kinetics of sarafloxacin, as a model of fluoroquinolone structure, were studied in the rat small intestine and in Caco-2 cells. The objective of the study was to investigate the mechanistic basis of the drug's intestinal transport in comparison with other members of the fluoroquinolone family and to apply a mathematical modelling approach to the transport process. In the rat small intestine, sarafloxacin showed dual mechanisms of intestinal absorption with a passive diffusional component and an absorptive carrier-mediated component. The characteristics of the animal study design made it suitable for population analysis, thus allowing the accurate estimation of transport param…

MaleAbsorption (pharmacology)Chemical PhenomenaAntimetabolitesPopulationPharmaceutical ScienceOxidative PhosphorylationIntestinal absorptionDiffusionchemistry.chemical_compoundAdenosine TriphosphateSarafloxacinAnti-Infective AgentsCiprofloxacinAnimalsHumansIntestinal MucosaRats WistarSodium AzideeducationAntibacterial agenteducation.field_of_studyModels StatisticalChemistry PhysicalBiological TransportLipidsRatsIntestinal AbsorptionchemistryBiochemistryPermeability (electromagnetism)BiophysicsSodium azideEffluxCaco-2 CellsEnergy MetabolismAlgorithmsFluoroquinolonesJournal of Drug Targeting
researchProduct

Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin

2005

Abstract The efflux process due to p-glycoprotein-like mechanisms of ciprofloxacin (CIP) and grepafloxacin (GRX) has been studied “in situ” in rats and “in vitro” in Caco-2 cells. The results were modelled by a curve fitting procedure which allowed the characterization of the passive (Pd) and carrier mediated parameters (Vm and Km) from the raw data without initial velocities estimation. CIP absorption in rat was characterized as a passive diffusion at the assayed concentrations. Although the involvement of an efflux transporter cannot be ruled out, its relevance in the transport of the fluoroquinolone is negligible. In GRX absorption, an efflux process is implicated and it is detected in b…

MaleAbsorption (pharmacology)In situCell Membrane PermeabilityPharmaceutical ScienceModels BiologicalPiperazinesDiffusionAnti-Infective AgentsCiprofloxacinIntestine SmallmedicineAnimalsHumansRats WistarAntibacterial agentChemistryTransporterIn vitroGrepafloxacinRatsPerfusionIntestinal AbsorptionBiochemistryPermeability (electromagnetism)BiophysicsEffluxCaco-2 CellsFluoroquinolonesmedicine.drugInternational Journal of Pharmaceutics
researchProduct

Effects of Ethanol on Intestinal Absorption of Drugs

1999

The effect of chronic alcohol intake on the intestinal absorption of seven compounds belonging to a homologous series (ciprofloxacin derivatives) was evaluated using an in situ rat gut technique that measures the intrinsic absorption rates of the compounds both in control and chronic alcohol-fed rats. For chronic alcohol treatment, the animals were fed a liquid diet containing ethanol (36% of calories), whereas an isocaloric diet was given to the pair-fed control animals. The biophysical absorption model, relating the intestinal absorption rate constants and partition indexes of the tested compounds, was then established either for control or alcohol-fed animals. Differences were analyzed a…

MaleAbsorption (pharmacology)Liquid dietEthanolEthanolCentral Nervous System DepressantsMedicine (miscellaneous)PharmacologyToxicologyIntestinal absorptionRatschemistry.chemical_compoundPsychiatry and Mental healthAnti-Infective AgentsIntestinal AbsorptionIntestinal mucosaBiochemistrychemistryPharmacokineticsCiprofloxacinOral administrationAnimalsRats WistarAntibacterial agentAlcoholism: Clinical & Experimental Research
researchProduct

Disposition of ciprofloxacin following intravenous administration in dogs

1994

The pharmacokinetics of ciprofloxacin (CIP) following intravenous administration in dogs have been investigated. The drug was administered at three doses (2.5, 5 and 10 mg/kg body weight) and was assayed in biological fluid samples (plasma and urine) by an HPLC method. The plasma concentration-time curves were best described by a two-compartment open pharmacokinetic model. The drug was widely distributed (Vd(area) almost 3 l/kg), being distributed in the dog more rapidly than in other species (t1/2(lambda 1) 3 min approximately). The elimination half-life (t1/2 lambda 2) was 129-180 min which is similar to values obtained in other species. The unchanged drug eliminated in urine was less tha…

MaleDrugmedia_common.quotation_subjectRenal functionUrinePharmacologyModels BiologicalBiological fluidDogsPharmacokineticsCiprofloxacinmedicineAnimalsChromatography High Pressure Liquidmedia_commonPharmacologyAnalysis of VarianceGeneral VeterinaryChemistryHalf-lifeCiprofloxacinRenal EliminationInjections IntravenousGlomerular Filtration RateHalf-Lifemedicine.drugJournal of Veterinary Pharmacology and Therapeutics
researchProduct

Escherichia coli of human and avian origin: detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy

2012

Objectives: Poultry have been suggested as a reservoir for fluoroquinolone-resistant extraintestinal pathogenic Escherichia coli (ExPEC). Our aim was to investigate whether genotypes associated with ciprofloxacin and multidrug resistance were shared among human and avian E. coli. Methods: We compared 277 human ExPEC isolates from urinary tract infection (UTI) and sepsis (142 susceptible and 135 ciprofloxacin resistant) and 101 avian isolates (68 susceptible and 33 ciprofloxacin resistant) by antimicrobial resistance phenotype, phylogenetic group and multilocus sequence type (ST). Results: Most ciprofloxacin-resistant isolates from both human and avian sources were multidrug resistant. Human…

MaleMicrobiology (medical)TurkeysSettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeBiologymedicine.disease_causeGroup AMicrobiologyAntibiotic resistanceDrug Resistance Multiple BacterialSepsisGenotypeEscherichia colimedicineAnimalsCluster AnalysisHumansPharmacology (medical)zoonosis urinary tract infections MLST molecular epidemiologyChildEscherichia coliEscherichia coli InfectionsPoultry DiseasesPharmacologyExtraintestinal Pathogenic Escherichia coliPhylogenetic treeInfantVirologyDrug Resistance MultipleAnti-Bacterial AgentsCiprofloxacinMultiple drug resistanceInfectious DiseasesItalyChild PreschoolUrinary Tract InfectionsFemaleChickensFluoroquinolonesMultilocus Sequence Typingmedicine.drug
researchProduct

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

2007

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

MaleRiskCancer Researchmedicine.medical_specialtyTime FactorsProstate biopsymedicine.drug_classUrologyAntibioticsUrologyProstatitisUnnecessary Proceduresurologic and male genital diseasesSettore MED/24 - UrologiaDiagnosis DifferentialProstate cancerCiprofloxacinBiopsyCarcinomaHumansMedicineUltrasonography InterventionalAgedAged 80 and overPalpationmedicine.diagnostic_testbusiness.industryPatient SelectionBiopsy NeedleProstateProstatic NeoplasmsCancerHistologyOrgan SizeMiddle AgedProstate-Specific Antigenmedicine.diseaseAnti-Bacterial AgentsProstatitisOncologybusinessprostate-specific antigen (PSA) prostatitis prostate carcinomaFollow-Up Studies
researchProduct

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

2016

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) acc…

MaleTORSADES-DE-POINTES INTERVAL PROLONGATION PATIENT CIPROFLOXACIN COHORT DEATH MULTIMORBIDITY AMIODARONE MORTALITY AIFA.Amiodarone030204 cardiovascular system & hematologyCIPROFLOXACINLogistic regressionAmiodaroneElectrocardiography0302 clinical medicineRisk FactorsTorsades de PointesAtrial Fibrillation80 and overPrevalencePharmacology (medical)030212 general & internal medicineAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalizationmedia_commonAged 80 and overTorsades de PointeAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Pharmacology (medical); Geriatrics and Gerontology; Medicine (all)Medicine (all)DEATHMiddle AgedPatient DischargeHospitalizationLong QT SyndromeCohortHospitalized Older PeopleFemalemedicine.drugHumanDrugmedicine.medical_specialtymedia_common.quotation_subjectMULTIMORBIDITYTorsades de pointesPATIENT03 medical and health sciencesPharmacotherapyInternal medicineINTERVAL PROLONGATIONmedicineHumansTORSADES-DE-POINTESCOHORTMedical prescriptionAIFAAgedbusiness.industryMORTALITYRisk FactorSettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseQT-Prolonging DrugAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Geriatrics and Gerontology; Pharmacology (medical)Physical therapyGeriatrics and Gerontologybusiness
researchProduct